A new standard of care for elderly patients with myeloma

摘要

New biologically-derived agents have changed the treatment of myeloma in the past 10 years Thalidomide, the first-in-class proteasome inhibitor bortezomib, and lenatidomide have all yielded encouraging results in overcoming drug resistance and improving outcome in relapsed and refractory patients with multiple myeloma1"3 Melphalan and prednisone (MP) have previously been the standard treatment for patients older than 65 years4 However, we now have extensive and confirmed evidence that MP plus thalidomide (MPT) is better than MP and should be the new standard of care for elderly patients with myeloma